Vericiguat is indicated for reducing hypertrophy, inflammation, and fibrosis in HF patients with EF below what threshold?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the Congestive Heart Failure Test. Access multiple choice questions and detailed explanations. Enhance your understanding of CHF and boost your confidence for the test day!

Multiple Choice

Vericiguat is indicated for reducing hypertrophy, inflammation, and fibrosis in HF patients with EF below what threshold?

Explanation:
Vericiguat’s approved use targets reducing adverse remodeling in heart failure with reduced ejection fraction, up to a specific EF cutoff based on the pivotal trial population. In VICTORIA, patients with EF ≤ 45% who were on guideline-directed therapy benefited from vericiguat, showing fewer cardiovascular deaths and heart failure hospitalizations. That trial-backed threshold defines the indication: EF below or equal to 45%. The other proposed cutoffs (lower or higher than 45%) don’t reflect the approved range.

Vericiguat’s approved use targets reducing adverse remodeling in heart failure with reduced ejection fraction, up to a specific EF cutoff based on the pivotal trial population. In VICTORIA, patients with EF ≤ 45% who were on guideline-directed therapy benefited from vericiguat, showing fewer cardiovascular deaths and heart failure hospitalizations. That trial-backed threshold defines the indication: EF below or equal to 45%. The other proposed cutoffs (lower or higher than 45%) don’t reflect the approved range.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy